UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO)

OFFICE ACTION (OFFICIAL LETTER) ABOUT APPLICANT’S TRADEMARK APPLICATION

 

 

 

OFFICE ACTION

 

STRICT DEADLINE TO RESPOND TO THIS LETTER

TO AVOID ABANDONMENT OF APPLICANT’S TRADEMARK APPLICATION, THE USPTO MUST RECEIVE APPLICANT’S COMPLETE RESPONSE TO THIS LETTER WITHIN 6 MONTHS OF THE ISSUE/MAILING DATE BELOW.

 

ISSUE/MAILING DATE: 11/11/2013

 

On Aptil 10^th, 2012, action on this application was suspended pending the disposition of U.S. Application Serial Nos. 77813913 and 85082269.  The referenced prior-pending applications have since registered.  Therefore, registration is refused as follows.

 

LIKELIHOOD OF CONFUSION – PARTIAL REFUSAL

 

With respect to all of International Class 5, and “electromagnetic medical diagnostic imaging apparatus,” “medical diagnostic instruments for the analysis of body fluids,” “MRI diagnostic apparatus,” “sample preparation device for medical diagnostic uses,” and “ultrasonic medical diagnostic apparatus; ultrasound diagnostic apparatus; x-ray diagnostic apparatus” in International Class 10 only, registration of the applied-for mark is refused because of a likelihood of confusion with the marks in U.S. Registration Nos. 4342924 and 4347021.  Trademark Act Section 2(d), 15 U.S.C. §1052(d); see TMEP §§1207.01 et seq.  See the enclosed registrations.

 

In any likelihood of confusion determination, two key considerations are similarity of the marks and similarity or relatedness of the goods.  Syndicat Des Proprietaires Viticulteurs De Chateauneuf-Du-Pape v. Pasquier DesVignes, 107 USPQ2d 1930, 1938 (TTAB 2013) (citing Federated Foods, Inc. v. Fort Howard Paper Co., 544 F.2d 1098, 1103, 192 USPQ 24, 29 (C.C.P.A. 1976)); In re Iolo Techs., LLC, 95 USPQ2d 1498, 1499 (TTAB 2010); see TMEP §1207.01.  That is, the marks are compared in their entireties for similarities in appearance, sound, connotation, and commercial impression.  In re Viterra Inc., 671 F.3d 1358, 1362, 101 USPQ2d 1905, 1908 (Fed. Cir. 2012) (quoting In re E. I. du Pont de Nemours & Co., 476 F.2d 1357, 1361, 177 USPQ 563, 567 (C.C.P.A. 1973)); TMEP §1207.01(b)-(b)(v).  Additionally, the goods are compared to determine whether they are similar or commercially related or travel in the same trade channels.  See Coach Servs., Inc. v. Triumph Learning LLC, 668 F.3d 1356, 1369-71, 101 USPQ2d 1713, 1722-23 (Fed. Cir. 2012); Herbko Int’l, Inc. v. Kappa Books, Inc., 308 F.3d 1156, 1165, 64 USPQ2d 1375, 1381 (Fed. Cir. 2002); TMEP §1207.01, (a)(vi).

 

A)    COMPARISON OF THE MARKS

 

Marks are compared in their entireties for similarities in appearance, sound, connotation, and commercial impression.  In re Viterra Inc., 671 F.3d 1358, 1362, 101 USPQ2d 1905, 1908 (Fed. Cir. 2012) (quoting In re E. I. du Pont de Nemours & Co., 476 F.2d 1357, 1361, 177 USPQ 563, 567 (C.C.P.A. 1973)); TMEP §1207.01(b)-(b)(v).  Similarity in any one of these elements may be sufficient to find the marks confusingly similar.  In re White Swan Ltd., 8 USPQ2d 1534, 1535 (TTAB 1988); see In re 1st USA Realty Prof’ls, Inc., 84 USPQ2d 1581, 1586 (TTAB 2007); TMEP §1207.01(b).

 

When comparing marks, the test is not whether the marks can be distinguished in a side-by-side comparison, but rather whether the marks are sufficiently similar in their entireties that confusion as to the source of the goods offered under applicant’s and registrant’s marks is likely to result.  Midwestern Pet Foods, Inc. v. Societe des Produits Nestle S.A., 685 F.3d 1046, 1053, 103 USPQ2d 1435, 1440 (Fed. Cir. 2012); Edom Labs., Inc. v. Lichter, 102 USPQ2d 1546, 1551 (TTAB 2012); TMEP §1207.01(b).  The focus is on the recollection of the average purchaser, who normally retains a general rather than specific impression of trademarks.  L’Oreal S.A. v. Marcon, 102 USPQ2d 1434, 1438 (TTAB 2012); Sealed Air Corp. v. Scott Paper Co., 190 USPQ 106, 108 (TTAB 1975); TMEP §1207.01(b).

 

Applicant’s mark is “SKYLA” with a design element.  Cited registrant’s marks are both “SKYLA” in standard characters.  The marks are similar because they both consist of the word “SKYLA,” which is cited registrant’s mark as a whole.

 

Marks may be confusingly similar in appearance where there are similar terms appearing in both applicant’s and registrant’s marks.  See Crocker Nat’l Bank v. Canadian Imperial Bank of Commerce, 228 USPQ 689 (TTAB 1986), aff’d sub nom. Canadian Imperial Bank of Commerce v. Wells Fargo Bank, Nat’l Ass’n, 811 F.2d 1490, 1 USPQ2d 1813 (Fed. Cir. 1987); In re BASF A.G., 189 USPQ 424 (TTAB 1975); TMEP §1207.01(b)(ii)-(iii).

 

Although applicant’s mark contains a design element, the word portions of the marks are nearly identical in appearance, sound, connotation, and commercial impression; therefore, the addition of a design element does not obviate the similarity of the marks in this case.  See In re Shell Oil Co., 992 F.2d 1204, 1206, 26 USPQ2d 1687, 1688 (Fed. Cir. 1993); TMEP §1207.01(c)(ii).

 

In addition, the marks are essentially phonetic equivalents and thus sound similar.  Similarity in sound alone may be sufficient to support a finding that the marks are confusingly similar.  In re White Swan Ltd., 8 USPQ2d 1534, 1535 (TTAB 1988); see In re 1st USA Realty Prof’ls, Inc., 84 USPQ2d 1581, 1586 (TTAB 2007); TMEP §1207.01(b)(iv).

 

Because the marks are comprised of identical wording, the marks are sufficiently similar to support a finding of likelihood of confusion.

 

B)    COMPARISON OF THE GOODS

 

The goods of the parties need not be identical or even competitive to find a likelihood of confusion.  See On-line Careline Inc. v. Am. Online Inc., 229 F.3d 1080, 1086, 56 USPQ2d 1471, 1475 (Fed. Cir. 2000); Recot, Inc. v. Becton, 214 F.3d 1322, 1329, 54 USPQ2d 1894, 1898 (Fed. Cir. 2000) (“[E]ven if the goods in question are different from, and thus not related to, one another in kind, the same goods can be related in the mind of the consuming public as to the origin of the goods.”); TMEP §1207.01(a)(i). 

 

The respective goods need only be “related in some manner and/or if the circumstances surrounding their marketing [be] such that they could give rise to the mistaken belief that [the goods] emanate from the same source.”  Coach Servs., Inc. v. Triumph Learning LLC, 668 F.3d 1356, 1369, 101 USPQ2d 1713, 1722 (Fed. Cir. 2012) (quoting 7-Eleven Inc. v. Wechsler, 83 USPQ2d 1715, 1724 (TTAB 2007)); Gen. Mills Inc. v. Fage Dairy Processing Indus. SA, 100 USPQ2d 1584, 1597 (TTAB 2011); TMEP §1207.01(a)(i).

 

Applicant’s refused goods are “amino acids for medical or veterinary purposes; bacterial and bacteriological preparations for medical or veterinary purposes; biochemical preparations for medical or veterinary purposes, namely, preparations for blood analysis and body fluid analysis; biological and chemical preparations and reagents for medical or veterinary use, namely, reagents for biochemistry analysis, immunoassay and nucleic acid testing; biological indicators for monitoring sterilization processes for medical or veterinary purposes; biological tissue cultures for veterinary purposes; chemical reagents for medical or veterinary purposes; clinical medical reagents for processing human whole blood and its components for use in blood transfusions stored in bags, bottles, syringes and other such containers used to store such substances in the medical field; diagnostic preparations for medical or veterinary purposes; diagnostic reagents and contrast media for medical use; drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; electrophoresis gels for medical or veterinary purposes; greases and petroleum jelly for medical or veterinary purposes; medical diagnostic reagents and assays for testing of body fluids; medical diagnostic reagents and assays for testing body fluids for microorganisms; medical diagnostic reagents for the analysis of body fluids; molecular complex for the delivery of non-radical oxygen for medicinal, surgical, therapeutic or veterinary purposes; nucleic acid sequences and chemical reagents for medical and veterinary purposes; plant extracts for medical, veterinary and pharmaceutical purposes; reagents and media for medical and veterinary diagnostic purposes; reagents for medical use” “electromagnetic medical diagnostic imaging apparatus,” “electromagnetic medical diagnostic imaging apparatus,” “medical diagnostic instruments for the analysis of body fluids,” “MRI diagnostic apparatus,” “sample preparation device for medical diagnostic uses,” and “ultrasonic medical diagnostic apparatus; ultrasound diagnostic apparatus; x-ray diagnostic apparatus.”

 

Cited registrant’s goods are “pharmaceuticals, namely, hormonal preparations” and “medical device, namely, an intrauterine device for contraception.”

 

With respect to the goods in International Class 5, the goods are related because they are all pharmaceutical preparations.  The Trademark Trial and Appeal Board and its primary reviewing court have used a stricter standard to determine likelihood of confusion for pharmaceuticals or medicinal products due to the potential harm or serious consequences that could be caused if the public confused one drug or medicinal product for another.  See Glenwood Labs., Inc. v. Am. Home Prods. Corp., 455 F.2d 1384, 1386-87, 173 USPQ 19, 21-22 (C.C.P.A. 1972); Schering Corp. v. Alza Corp., 207 USPQ 504, 509 (TTAB 1980); Ethicon, Inc. v. Am. Cyanamid Co., 192 USPQ 647, 651-52 (TTAB 1976); TMEP §1207.01(d)(xii).  Although physicians and pharmacists are no doubt carefully trained to recognize differences in the characteristics of pharmaceuticals or medicinal products, they are not immune from mistaking similar trademarks used on these goods.  See Alfacell Corp. v. Anticancer Inc., 71 USPQ2d 1301, 1305-06 (TTAB 2004); Blansett Pharmacal Co. v. Carmrick Labs., Inc., 25 USPQ2d 1473, 1477 (TTAB 1992); Schering Corp., 207 USPQ at 509.  Thus, in this case where confusion could result in harm or other serious consequences to consumers, this potential harm is considered an additional relevant factor and a lesser degree of proof may be sufficient to establish a likelihood of confusion.  See Glenwood Labs., Inc., 455 F.2d at 1386-87, 173 USPQ at 21-22; Schering Corp., 207 USPQ at 509; Ethicon, Inc., 192 USPQ at 651-52; TMEP §1207.01(d)(xii).

 

And with respect to the refused goods in International Class 10, the goods are related cited registrant’s contraception device because they could be used to diagnose or detect fertility, conception, or pregnancy.  With respect to applicant’s and registrant’s goods, the question of likelihood of confusion is determined based on the description of the goods stated in the application and registration at issue, not on extrinsic evidence of actual use.  See, e.g., Coach Servs., Inc. v. Triumph Learning LLC, 668 F.3d 1356, 1369-70, 101 USPQ2d 1713, 1722 (Fed. Cir. 2012); Octocom Sys. Inc. v. Hous. Computers Servs. Inc., 918 F.2d 937, 942, 16 USPQ2d 1783, 1787 (Fed. Cir. 1990). 

 

Absent restrictions in an application and/or registration, the identified goods are “presumed to travel in the same channels of trade to the same class of purchasers.”  In re Viterra Inc., 671 F.3d 1358, 1362, 101 USPQ2d 1905, 1908 (Fed. Cir. 2012) (quoting Hewlett-Packard Co. v. Packard Press, Inc., 281 F.3d 1261, 1268, 62 USPQ2d 1001, 1005 (Fed. Cir. 2002)).  Additionally, unrestricted and broad identifications are presumed to encompass all goods of the type described.  See In re Jump Designs, LLC, 80 USPQ2d 1370, 1374 (TTAB 2006) (citing In re Elbaum, 211 USPQ 639, 640 (TTAB 1981)); In re Linkvest S.A., 24 USPQ2d 1716, 1716 (TTAB 1992). 

 

In this case, the identifications set forth in the application and registration have no restrictions as to nature, type, channels of trade, or classes of purchasers.  Therefore, it is presumed that these goods travel in all normal channels of trade, and are available to the same class of purchasers.  Further, the application uses broad wording that does not exclude use for reproductive or contraceptive detection, diagnosis, or prevention.

 

Because the marks are similar and the goods are related, a likelihood of confusion exists to prevent registration of applicant’s mark under Section 2(d) of the Trademark Act for all of International Class 5, and “electromagnetic medical diagnostic imaging apparatus,” “medical diagnostic instruments for the analysis of body fluids,” “MRI diagnostic apparatus,” “sample preparation device for medical diagnostic uses,” and “ultrasonic medical diagnostic apparatus; ultrasound diagnostic apparatus; x-ray diagnostic apparatus” in International Class 10 only.

 

RESPONDING TO A PARTIAL REFUSAL

 

Applicant may respond to the stated refusal by submitting evidence and arguments against the refusal.  In addition, applicant may respond by doing one of the following:

 

(1)        Deleting the goods to which the refusal pertains;

 

(2)        Filing a request to divide out the goods that have not been refused registration, so that the mark may proceed toward publication for opposition for those goods to which the refusal does not pertain.  See 37 C.F.R. §2.87.  See generally TMEP §§1110 et seq. (regarding the requirements for filing a request to divide).  If applicant files a request to divide, then to avoid abandonment, applicant must also file a timely response to all outstanding issues in this Office action, including the refusal.  37 C.F.R. §2.87(e).

 

PARTIAL ABANDONMENT ADVISORY

 

If applicant does not respond to this Office action within the six-month period for response, the following goods will be deleted from the application:

 

International Class 5 – ENTIRE CLASS

 

International Class 10 – “Electromagnetic medical diagnostic imaging apparatus,” “medical diagnostic instruments for the analysis of body fluids,” “MRI diagnostic apparatus,” “sample preparation device for medical diagnostic uses,” and “ultrasonic medical diagnostic apparatus; ultrasound diagnostic apparatus; x-ray diagnostic apparatus.”

 

The application will then proceed with the following goods only:

 

International Class 10 – “Blood pressure and diabetic diagnostic medical devices; Breath gas analyzers for medical diagnostics; Cytometers for medical diagnostic use; Diagnostic apparatus for the detection of periodontal disease; Diagnostic apparatus for the detection of cancer; Diagnostic kits consisting primarily of probes, buffers and reagents for use in microbial testing; Dynamometers for diagnostic muscle strength testing; Flow cytometers and flow-based analyzers providing cell and particle analysis, detection, or counting for medical, clinical, medical diagnostic, and therapeutic uses; Flow cytometers for medical diagnostic uses; Hematology analyzers for medical diagnostic uses; Instrument and apparatus systems for medical diagnostic uses consisting of flow cytometers, hematology analyzers, sample preparation device, and related data management software sold as a unit; Medical apparatus and instruments for diagnostic radiopharmaceutical use; Medical apparatus and instrument for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; Medical diagnostic apparatus, analytical apparatus for medical purposes and blood pressure measuring apparatus; Medical diagnostic apparatus for detecting cancer; Medical dose meter that measures the total radiation dose received by a patient during a diagnostic procedure; Medical instrument for cardiovascular diagnostics; Nuclear medicine diagnostic imaging apparatus; Organoleptic diagnostic testing apparatus for medical, dental or cosmetic use; Orthopedic apparatus and instruments for diagnostic and therapeutic use; Orthopedic devices for diagnostic and therapeutic use; Radiological apparatus for diagnostic and medical purposes, namely, magnetic resonance imager; Radiological apparatus for diagnostic and medical purposes, namely, a helium-3 polarizer used for magnetic resonance imaging (MRI) of the lungs; Ultrasonic bone densitometer with computer, printer, and computer software for use therewith, sold as a unit, for medical diagnostic use.”

 

See 37 C.F.R. §2.65(a); TMEP §718.02(a).

 

If applicant has questions regarding this Office action, please telephone or e-mail the assigned trademark examining attorney.  All relevant e-mail communications will be placed in the official application record; however, an e-mail communication will not be accepted as a response to this Office action and will not extend the deadline for filing a proper response.  See 37 C.F.R. §2.191; TMEP §§304.01-.02, 709.04-.05.  Further, although the trademark examining attorney may provide additional explanation pertaining to the refusal in this Office action, the trademark examining attorney may not provide legal advice or statements about applicant’s rights.  See TMEP §§705.02, 709.06.

 

 

/Jason Paul Blair/

Examining Attorney

Law Office 104

Phone - (571) 272-8856

Fax - (571) 273-8856

jason.blair@uspto.gov

 

TO RESPOND TO THIS LETTER:  Go to http://www.gov.uspto.report/trademarks/teas/response_forms.jsp.  Please wait 48-72 hours from the issue/mailing date before using the Trademark Electronic Application System (TEAS), to allow for necessary system updates of the application.  For technical assistance with online forms, e-mail TEAS@uspto.gov.  For questions about the Office action itself, please contact the assigned trademark examining attorney.  E-mail communications will not be accepted as responses to Office actions; therefore, do not respond to this Office action by e-mail.

 

All informal e-mail communications relevant to this application will be placed in the official application record.

 

WHO MUST SIGN THE RESPONSE:  It must be personally signed by an individual applicant or someone with legal authority to bind an applicant (i.e., a corporate officer, a general partner, all joint applicants).  If an applicant is represented by an attorney, the attorney must sign the response. 

 

PERIODICALLY CHECK THE STATUS OF THE APPLICATION:  To ensure that applicant does not miss crucial deadlines or official notices, check the status of the application every three to four months using the Trademark Status and Document Retrieval (TSDR) system at http://tsdr.gov.uspto.report/.  Please keep a copy of the TSDR status screen.  If the status shows no change for more than six months, contact the Trademark Assistance Center by e-mail at TrademarkAssistanceCenter@uspto.gov or call 1-800-786-9199.  For more information on checking status, see http://www.gov.uspto.report/trademarks/process/status/.

 

TO UPDATE CORRESPONDENCE/E-MAIL ADDRESS:  Use the TEAS form at http://www.gov.uspto.report/trademarks/teas/correspondence.jsp.

 

UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO)

 

 

IMPORTANT NOTICE REGARDING YOUR

U.S. TRADEMARK APPLICATION

 

USPTO OFFICE ACTION (OFFICIAL LETTER) HAS ISSUED

ON 11/11/2013 FOR U.S. APPLICATION SERIAL NO. 85467218

 

Please follow the instructions below:

 

(1)  TO READ THE LETTER:  Click on this link or go to http://tsdr.uspto.gov,enter the U.S. application serial number, and click on “Documents.”

 

The Office action may not be immediately viewable, to allow for necessary system updates of the application, but will be available within 24 hours of this e-mail notification.

 

(2)  TIMELY RESPONSE IS REQUIRED:  Please carefully review the Office action to determine (1) how to respond, and (2) the applicable response time period.  Your response deadline will be calculated from 11/11/2013 (or sooner if specified in the Office action).  For information regarding response time periods, see http://www.gov.uspto.report/trademarks/process/status/responsetime.jsp.

 

Do NOT hit “Reply” to this e-mail notification, or otherwise e-mail your response because the USPTO does NOT accept e-mails as responses to Office actions.  Instead, the USPTO recommends that you respond online using the Trademark Electronic Application System (TEAS) response form located at http://www.gov.uspto.report/trademarks/teas/response_forms.jsp.

 

(3)  QUESTIONS:  For questions about the contents of the Office action itself, please contact the assigned trademark examining attorney.  For technical assistance in accessing or viewing the Office action in the Trademark Status and Document Retrieval (TSDR) system, please e-mail TSDR@uspto.gov.

 

WARNING

 

Failure to file the required response by the applicable response deadline will result in the ABANDONMENT of your application.  For more information regarding abandonment, see http://www.gov.uspto.report/trademarks/basics/abandon.jsp.

 

PRIVATE COMPANY SOLICITATIONS REGARDING YOUR APPLICATION:  Private companies not associated with the USPTO are using information provided in trademark applications to mail or e-mail trademark-related solicitations.  These companies often use names that closely resemble the USPTO and their solicitations may look like an official government document.  Many solicitations require that you pay “fees.” 

 

Please carefully review all correspondence you receive regarding this application to make sure that you are responding to an official document from the USPTO rather than a private company solicitation.  All official USPTO correspondence will be mailed only from the “United States Patent and Trademark Office” in Alexandria, VA; or sent by e-mail from the domain “@uspto.gov.”  For more information on how to handle private company solicitations, see http://www.gov.uspto.report/trademarks/solicitation_warnings.jsp.